RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MOSCA A
Collezione AOU San Luigi di Orbassano

Items : 16

The real-time intraoperative guidance of the new HIFU Focal-One(®) platform allows to minimize the perioperative adverse events in salvage setting. in Journal of ultrasound / J Ultrasound. 2022 Jun;25(2):225-232. doi: 10.1007/s40477-021-00594-8. Epub 2021 May 24.

2022
AOU San Luigi di Orbassano

Manfredi M; Volpi G; Amparore D; Verri P; Poti C; Rescigno P; Russo F; Belli G; Galla A; Mosca A; Garrou D; Piramide F; De Luca S; Checcucci E; Fiori C; Porpiglia F;

Molecular Characterization of Prostate Cancers in the Precision Medicine Era. in Cancers / Cancers (Basel). 2021 Sep 24;13(19):4771. doi: 10.3390/cancers13194771.

2021
AOU San Luigi di Orbassano

Giunta EF; Annaratone L; Bollito E; Porpiglia F; Cereda M; Banna GL; Mosca A; Marchiò C; Rescigno P;

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. in Drug and alcohol dependence / Drug Alcohol Depend. 2021 Dec 1;229(Pt A):109118. doi: 10.1016/j.drugalcdep.2021.109118. Epub 2021 O

2021
AOU San Luigi di Orbassano

Ricci V; Ceci F; Di Carlo F; Lalli A; Ciavoni L; Mosca A; Sepede G; Salone A; Quattrone D; Fraticelli S; Maina G; Martinotti G;

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.

2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Procopio G; Mucciarini C; Mosca A; Massari F; Masini C; Fratino L; Ermacora P; Fornarini G; Donini M; Ceresoli GL; Buti S; Bortolus R; Berruti A; Baldessari C; Zagonel V; Caffo O; Buttigliero C; Zucali P; Verri E;

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2009;12(1):94-9. doi: 10.1038/pcan.2008.10. Epub 2008 Mar 11.

2009
AOU San Luigi di Orbassano

Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A;

Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. in The Journal of urology / J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16.

2007
AOU San Luigi di Orbassano

Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L;

[Optimization of treatment options through a multidisciplinary approach for advanced hormone refractory prostate carcinoma]. in Tumori / Tumori. 2007 Mar-Apr;93(2):suppl 17-23.

2007
AOU San Luigi di Orbassano

Dogliotti L; Mosca A;

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. in British journal of cancer / Br J Cancer. 2005 Sep 19;93(6):633-8. doi: 10.1038/sj.bjc.6602767.

2005
AOU San Luigi di Orbassano

Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L;

Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients. in Anticancer research / Anticancer Res. 2005 Nov-Dec;25(6C):4475-9.

2005
AOU San Luigi di Orbassano

Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L;

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. in Urologic oncology / Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003.

2005
AOU San Luigi di Orbassano

Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. in Journal of endocrinological investigation / J Endocrinol Invest. 2005;28(11 Suppl International):141-5.

2005
AOU San Luigi di Orbassano

Mosca A; Berruti A; Russo L; Torta M; Dogliotti L;

Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer. in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver / Dig Liver Dis. 2004 Feb;36 Suppl 1:S60-7. doi: 10.1016/j.dld.2003.11.021.

2004
AOU San Luigi di Orbassano

Mosca A; Dogliotti L; Berruti A; Lamberts SW; Hofland LJ;

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. in The Prostate / Prostate. 2001 May 15;47(3):205-11. doi: 10.1002/pros.1064.

2001
AOU San Luigi di Orbassano

Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A;

Circulating neuroendocrine markers in patients with prostate carcinoma. in Cancer / Cancer. 2000 Jun 1;88(11):2590-7. doi: 10.1002/1097-0142(20000601)88:11<2590::aid-cncr23>3.0.co;2-d.

2000
AOU San Luigi di Orbassano

Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A;

Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer. in The Journal of urology / J Urol. 1999 Jan;161(1):176-81.

1999
AOU San Luigi di Orbassano

Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A;